Claims for Patent: 9,499,619

Summary for Patent: 9,499,619

Title:	Polyclonal bispecific antibody compositions and method of use
Abstract:	The invention relates to compositions and methods for treating a host infected with a pathogen. The composition comprising a population of polyclonal bispecific binding molecules that can target and eliminate a host cell infected with the pathogen. Methods for activating and arming cytotoxic immune cells with the composition for use in treating a patient infected with a pathogen are also provided.
Inventor(s):	Lum; Lawrence G. (Harrison Township, MI), Huang; Manley (Palo Alto, CA)
Assignee:	TRANSTARGET, INC. (Burlingame, CA) WAYNE STATE UNIVERSITY (Detroit, MI)
Application Number:	14/637,194
Patent Claims:	1. A composition comprising a heterogeneous population of polyclonal bispecific binding molecules, where each bispecific binding molecule comprises a first and a second antigen binding moiety, wherein the first antigen binding moieties specifically bind to an antigen on the surface of a cytotoxic immune cell, said first antigen binding moieties being the same or different, and wherein the second antigen binding moieties are a heterogeneous polyclonal population of antigen binding moieties against multiple different epitopes on one or more pathogenic antigens expressed or presented on the surface of a cell infected with the pathogen, said antigens being the same or different, wherein the first antigen binding moiety is fused to the second antigen binding moiety to form the bispecific binding molecule. 2. The composition of claim 1, wherein the cytotoxic immune cell is selected from the group consisting of an activated T-cell, a natural killer (NK) cell, a dendritic cell, and a macrophage. 3. The composition of claim 1, wherein the first binding moiety and the second binding moiety are antibodies or antigen binding fragments thereof. 4. The composition of claim 3, wherein the first binding moiety is a monoclonal antibody or antigen binding fragment thereof and the second binding moiety comprises a population of polyclonal antibodies or an antigen binding fragments thereof. 5. The composition of claim 4, wherein the heterogeneous population of polyclonal bispecific binding molecules comprises at least two different antibodies as second antigen binding moieties with each antibody having different antigen recognition specificity and being directed to different epitopes on the pathogen. 6. The composition of claim 4, wherein the population of polyclonal antibodies is derived from an immunoglobulin (Ig) enriched serum fraction. 7. The composition of claim 6, wherein the Ig serum fraction is depleted of antibodies that recognize human leukocyte antigen (HLA) molecules. 8. The composition of claim 4, wherein the polyclonal antibody is derived from an autologous donor. 9. The composition of claim 4, wherein the polyclonal antibody is derived from an allogeneic donor, or a pool of allogeneic donors. 10. The composition of claim 1, wherein the cytotoxic immune cell is derived from an autologous donor. 11. The composition of claim 1, wherein the cytotoxic immune cell is derived from an allogeneic donor. 12. The composition of claim 1, wherein the first antigen binding moiety specifically binds to a molecule selected from the group consisting of CD2, CD3, CD4, CD5, CD8, CD11b, CD14, CD16a, CD28, CD45 and CD56. 13. The composition of claim 12, wherein the first antigen binding moiety is an anti-CD3 antibody, or functional equivalent, or antigen binding fragment thereof. 14. The composition of claim 13, wherein the anti-CD3 antibody is OKT3 or a functional equivalent. 15. The composition of claim 1, wherein the cytotoxic immune cell is armed with the population of polyclonal bispecific binding molecules. 16. The composition of claim 1, wherein the first antigen binding moiety specifically binds to an Fc receptor. 17. The composition of claim 15, wherein the arming dose of the population of polyclonal bispecific binding molecules is in the range of 0.001 ng to 50 ng per 106 cytotoxic immune cells. 18. The composition of claim 15, wherein the arming dose of the population of polyclonal bispecific binding molecules is in the range of 0.01 ng to 5 ng per 106 cytotoxic immune cells. 19. The composition of claim 15, wherein the arming dose of the population of polyclonal bispecific binding molecules is in the range of 0.1 ng to 1.0 ng per 106 cytotoxic immune cells. 20. The composition of claim 1, wherein the pathogen is an infectious agent. 21. The composition of claim 20, wherein the infectious agent is selected from the group consisting of a virus, a bacterium, a fungus, and a parasite. 22. The composition of claim 21, wherein the pathogen is a virus. 23. The composition of claim 22, wherein the virus is selected from the group consisting of cytomegalovirus (CMV), hepatitis A virus (HAV), hepatitis virus type B (HBV), hepatitis virus type C (HCV), Epstein-Barr virus (EBV), BK virus (BKV), herpes simplex virus (HSV), human immunodeficiency virus (HIV), and human papilloma virus (HPV). 24. The composition of claim 23, wherein the virus is CMV. 25. The composition of claim 21, wherein the population of second antigen binding moieties is derived from an IVIG preparation. 26. The composition of claim 25, wherein the IVIG preparation is CYTOGAM. 27. The composition of claim 21, wherein the pathogen is a fungus. 28. The composition of claim 27, wherein the fungus is Pneumocystis carinii or aspergillus.

Details for Patent 9,499,619

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Kamada Ltd.	CYTOGAM	cytomegalovirus immune globulin intravenous (human)	Injection	103189	April 17, 1990	9,499,619	2029-11-06